GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Cyclically Adjusted PB Ratio

Traws Pharma (Traws Pharma) Cyclically Adjusted PB Ratio : 0.00 (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Traws Pharma's current share price is $0.6207. Traws Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $472.99. Traws Pharma's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Traws Pharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Traws Pharma's highest Cyclically Adjusted PB Ratio was 0.40. The lowest was 0.10. And the median was 0.20.

TRAW's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Traws Pharma's adjusted book value per share data for the three months ended in Mar. 2024 was $0.285. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $472.99 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Traws Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Traws Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Cyclically Adjusted PB Ratio Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.40 - -

Traws Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Traws Pharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Cyclically Adjusted PB Ratio falls into.



Traws Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Traws Pharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.6207/472.99
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Traws Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.285/131.7762*131.7762
=0.285

Current CPI (Mar. 2024) = 131.7762.

Traws Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 5,038.318 100.560 6,602.364
201409 3,658.610 100.428 4,800.640
201412 2,357.306 99.070 3,135.538
201503 1,218.446 99.621 1,611.729
201506 387.681 100.684 507.401
201509 319.848 100.392 419.840
201512 884.276 99.792 1,167.689
201603 491.708 100.470 644.920
201606 99.918 101.688 129.482
201609 305.759 101.861 395.556
201612 143.043 101.863 185.050
201703 -117.641 102.862 -150.709
201706 -8.862 103.349 -11.300
201709 -157.789 104.136 -199.671
201712 -244.224 104.011 -309.418
201803 -89.240 105.290 -111.689
201806 42.072 106.317 52.147
201809 28.709 106.507 35.520
201812 14.241 105.998 17.704
201903 -3.908 107.251 -4.802
201906 -11.368 108.070 -13.862
201909 -11.054 108.329 -13.447
201912 1.562 108.420 1.898
202003 1.913 108.902 2.315
202006 1.346 108.767 1.631
202009 0.993 109.815 1.192
202012 0.498 109.897 0.597
202103 2.355 111.754 2.777
202106 2.091 114.631 2.404
202109 2.377 115.734 2.706
202112 2.207 117.630 2.472
202203 2.024 121.301 2.199
202206 1.842 125.017 1.942
202209 1.595 125.227 1.678
202212 1.353 125.222 1.424
202303 1.091 127.348 1.129
202306 0.901 128.729 0.922
202309 0.691 129.860 0.701
202312 0.508 129.419 0.517
202403 0.285 131.776 0.285

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Traws Pharma  (NAS:TRAW) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Traws Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (Traws Pharma) Business Description

Industry
Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Executives
Victor M Moyo officer: CHIEF MEDICAL OFFICER 12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke director 12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja director 12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler officer: VP Corp Dev & Gen Counsel C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman officer: Chief Medical Officer 375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md officer: Chief Medical Officer C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin officer: Chief Accounting Officer 375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker director 375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy director 375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman director C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta director OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P 10 percent owner 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022